anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
FIELD: medicine. SUBSTANCE: method involves applying medicamentous therapy. 2% zinc sulfate and 3% sodium thiosulfate electrophoresis is additionally carried out using 3-electrode method. 150 cm 2  area anodes are arranged on anterior abdominal surface in the liver and pancreas projection zones. 150 cm 2  area cathode is placed in the area of inferior thoracic region of the vertebral column. Procedure duration is 15-25 min. The total course is 10-15 procedures long. EFFECT: enhanced effectiveness of treatment; stable treatment result.
The cerebral vasculature manages oxygen delivery by adjusting arterial blood in-flow in the face of reductions in oxygen availability. Hypoxic cerebral vasodilatation, and the associated hypoxic cerebral blood flow reactivity, involve many vascular, erythrocytic and cerebral tissue mechanisms that mediate elevations in cerebral blood flow via micro- and macrovascular dilatation. This contemporary review focuses on in vivo human work - with reference to seminal preclinical work where necessary - on hypoxic cerebrovascular reactivity, particularly where recent advancements have been made. We provide updates with the following information: in humans, hypoxic cerebral vasodilatation is partially mediated via a - likely non-obligatory - combination of: (1) nitric oxide synthases, (2) deoxygenation-coupled S-nitrosothiols, (3) potassium channel-related vascular smooth muscle hyperpolarization, and (4) prostaglandin mechanisms with some contribution from an interrelationship with reactive oxygen species. And finally, we discuss the fact that, due to the engagement of deoxyhaemoglobin-related mechanisms, reductions in O2 content via haemoglobin per se seem to account for ∼50% of that seen with hypoxic cerebral vasodilatation during hypoxaemia. We further highlight the issue that methodological impediments challenge the complete elucidation of hypoxic cerebral reactivity mechanisms in vivo in healthy humans. Future research is needed to confirm recent advancements and to reconcile human and animal findings. Further investigations are also required to extend these findings to address questions of sex-, heredity-, age-, and disease-related differences. The final step is to then ultimately translate understanding of these mechanisms into actionable, targetable pathways for the prevention and treatment of cerebral vascular dysfunction and cerebral hypoxic brain injury.
<P>PROBLEM TO BE SOLVED: To provide an agent for treating hepatic disease effective for treating viral hepatitises such as hepatitis B and C and also hepatic diseases such as hepatic cirrhosis and hepatic cancer resulted from the viral hepatitises.  <P>SOLUTION: The agent for treating hepatic disease containing a human Th1 cell or a human Th2 cell is provided. A treating agent containing new Th1 cell and Th2 cell is provided for the viral hepatitis, the hepatic cirrhosis and the hepatic cancer. The agent can be used together with an existing antiviral agent such as IFN and also can be used for recurrence prevention after surgical excision of the hepatic cancer. Thereby, the agent is medically remarkably useful since the treatment effect of the hepatic disease which is not sufficient up to now is improved.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:To provide an emulsifying dispersant capable of stably emulsifying and dispersing various substances, obtained by containing an org. boron compound represented by a specific general formula as an effective component. CONSTITUTION:An emulsifying dispersant containing one or more of an org. boron compound represented by general formula [wherein X, X', Y, Y', are hydrogen atom, a methyl group, an ethyl group or an -(C2H4-) containing long chain group] as an effective component and can form either one of an O/W type emulsion and a W/O type emulsion. As this emulsifying dispersant, (glycerine octadecenylsuccinoyl glycerine) borate is pref. used and can by easily prepared by a method wherein di(polyol) borate and succinic acid are subjected to condensation reaction under heating to form acid ester which is, in turn, contacted with monovalent hydroxide such as sodium hydroxide at about 0-150 deg.C under atmospheric pressure or high pressure in the presence of water or a hydrophilic solvent.
PROBLEM TO BE SOLVED: To obtain an antimalarial agent useful for treatment and prevention of malaria and having both high usefulness and safety by including a specified compound. SOLUTION: This antimalarial agent is obtained by including a compound of the formula [R1 and R2 are each H, a halogen, OH, a (substituted) 1-5C alkyl or the like, or R1 and R2 are linked each other to form a six-membered ring; R3 and R5 are each a (substituted) 1-8C alkyl; R4 is a (substituted) alkyl or a (substituted) 6-8C aryl; R6 and R7 are each H, chlorine, a (substituted) 1-8C alkyl or the like, or R6 and R7 are linked each other to form a 6-membered rig which may be condensed with another ring; Z is an atomic group necessary for making five or six-membered heterocycle; Q is an anion (e.g. chlorine ion); and (k) is (1) or 2] e.g. a compound of formula II. The compound of formula I is prepared by conventional methods. The daily dose is 0.1-1,000 mg preferably 1-600 mg for adult and is preferably administered once a day or in 2-4 divided doses.
Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
During summer, farmed Atlantic salmon (Salmo salar) can experience prolonged periods of warming and low aquatic oxygen levels due to climate change. This often results in a drop in feed intake; however, the physiological mechanism behind this behaviour is unclear. Digestion is a metabolically expensive process that can demand a high proportion of an animal's energy budget and might not be sustainable under future warming scenarios. We investigated the effects of elevated temperature and acute hypoxia on specific dynamic action (SDA; the energetic cost of digestion), and how much of the energy budget (i.e. aerobic scope, AS) was occupied by SDA in juvenile Atlantic salmon. AS was 9% lower in 21°C-acclimated fish compared to fish reared at their optimum temperature (15°C) and was reduced by ~50% by acute hypoxia (50% air saturation) at both temperatures. Furthermore, we observed an increase in peak oxygen uptake rate during digestion which occupied ~13% of the AS at 15°C and ~20% of AS at 21°C, and increased the total cost of digestion at 21°C. The minimum oxygen tolerance threshold in digesting fish was ~42% and ~53% at 15 and 21°C, respectively, and when digesting fish were exposed to acute hypoxia, gut transit was delayed. Thus, these stressors result in a greater proportion of the available energy budget being directed away from digestion. Moderate environmental hypoxia under both optimal and high temperatures severely impedes digestion and should be avoided to limit exacerbating temperature effects on fish growth.
For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum \[ac\] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily \[od\] in the morning).
INTRODUCTION: Cataract surgery in patients after penetrating keratoplasty (PKP) is often challenging because of changes in corneal structure induced by PKP and primary corneal disease. Femtosecond laser-assisted cataract surgery offers several advantages over conventional phacoemulsification, and has been widely used in complicated cataract surgery.
CASE REPORT: We report the use of femtosecond laser-assisted cataract surgery in 3 challenging cases after penetrating keratoplasty. Case 1 involved a patient with hard nuclear grade IV° cataract. After surgery, his corrected distance visual acuity (CDVA) improved from 20/400 to 20/25, and the endothelial cell loss (ECL) % was 12.05 % at 3 months postoperatively. The rotation of the toric IOL in Case 1 was 2°. Case 2 involved a patient with severe nuclear cataract and an endothelial cell density of 837 cells/mm2. After surgery, the CDVA improved from 20/100 to 20/40. The ECL% was 4.06% at 1 week postoperatively. Case 3 was a 91-year-old woman with a short axis length of 21.35 mm and an endothelial cell density number of 1238 cells/mm2. After surgery, the CDVA improved from light perception to 20/133, and the ECL% was 26.09% at 1 week postoperatively; ECL% was 2.67% at 1 month post-operation. The corneal grafts were transparent.
CONCLUSION: Femtosecond laser-assisted cataract surgery seems to be an effective, predictable, and safe approach for challenging patients after PKP, and improves visual recovery and optimal refractive outcomes.
PURPOSE:To improve water resistance, heat resistance, scratch resistance, adhesive resistance and swelling resistance by incorporating a specified activating reagent in an alkali-treated gelatin to activate carboxyl groups of side chains of gelatin and amidating it with a nucleophilic reagent. CONSTITUTION:An alkali-treated gelatin is incorporated with 5-20wt.% at least one compd. selected from carbodiimide reagents and salts thereof of the formula (wherein R is ethyl, cyclohexyl or benzyl; R' is dimethylaminopropyl, cyclohexyl or morpholinoethyl) to activate carboxyl groups of the side chains of gelatin. Then, 0.1-10wt.% said gelatin is incorporated in an aq. soln. contg. 0.5-6mol of a nucleophilic reagent (e.g. NH4Cl) and the mixture is reacted at a pH of 3.0-6.5, at 30-70 deg.C for 1-12hr and the activated carboxyl groups are amidated to obtain an improved alkali-treated gelatin wherein an iso-ionic point is at a pH of 7-10.5.
C. Volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. B. After a 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. Finally and after a last 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes.
During the COVID-19 pandemic, the education and healthcare sectors were severely affected. There is a need to investigate the ways in which these workers in at-risk sectors can be protected and through what mechanisms. The aims of this research are, therefore, (1) to assess the mediating role of job demands and resources in the relationship between psychosocial safety climate (PSC) and work engagement and emotional exhaustion, and (2) to test for sector-specific differences among education and healthcare professionals during the COVID-19 pandemic. In the study, which employed a longitudinal design including three measurement times, 70 education professionals and 69 healthcare professionals completed a questionnaire measuring PSC, psychological demands, social support, recognition, work engagement, and emotional exhaustion. The results show that PSC was significantly higher among education professionals than among healthcare professionals. When considering both job sectors together, mediation analyses show that social support mediates the PSC-work engagement relationship, while psychological demands mediate the PSC-emotional exhaustion relationship. Moderated mediation analyses show that job sector is a moderator: among education professionals, colleague support and recognition mediate the PSC-work engagement relationship, and psychological demands mediate the PSC-emotional exhaustion relationship. PSC is associated with more balanced job demands and resources, higher work engagement, and lower emotional exhaustion among education and healthcare professionals. The study of these two sectors, which are both vital to society but also more exposed to adverse work conditions, shows the importance that managers and executives must attach to their mental health by improving their respective working conditions.
The invention relates to a cosmetic and dermatological agent containing magnetically hard particles and other active ingredients. Said agent has a coercive force of between 80,000 and 1,600,000 A/m, and contains between 0.0001 and 2 wt. % of magnetically hard particles, preferably barium hexaferrite monocrystals of between 80 and 550 nm, between 0.0001 and 0.05 wt. % of a ground jade stone of between 50 and 95 nm, and cosmetic or dermatological auxiliary and carrier substances up to 100 wt. %. The invention also relates to a method for producing said agent, and to the use thereof for increasing microcirculation, the local regulation of microcirculation, and the immune defence in the skin.
The invention creatively provides a traditional Chinese medicine composition suitable for eye health caring for luminous screen users. The traditional Chinese medicine composition includes, by weight, 5-20 parts of burdock, 5-10 parts of angelica sinensis, 5-20 parts of astragalus membranaceus, 5-10 parts of honeysuckles, 5-10 parts of chrysanthemum, 5-15 parts of fructus lycii, and 5-10 parts of semen cassiae. The invention also creatively provides a traditional Chinese medicine preparation with the traditional Chinese medicine composition. According to the character that eyes like cold but are intolerant of hot, eye health caring is achieved with the traditional Chinese medicines activating blood and promoting eyes with the traditional Chinese medicines being warm and nourishing body, so that symptoms of dry astringent and red and swollen eyes, blurred vision and the like of the luminous screen users can be alleviated effectively. The cold medicines have no influence on body health. The traditional Chinese medicine composition is also suitable for female white-collar office workers who have deficiency of yin.
PROBLEM TO BE SOLVED: To obtain the subject new compound excellent in antihistaminic activity and antiallergic activity, having a few hygroscopic property, excellent in physicochemical property and useful as a medicine. SOLUTION: This new compound is benzenesulfonic acid salt of a compound represented by formula I. The new compound is preferably obtained by subjecting 1 mol compound of formula I to salt formation reaction with 0.9-1.2 mol benzenesulfonic acid in a solvent such as ethyl acetate, preferably at 10-35 deg.C. The solvent is preferably used in an amount of 1 to 10 L based on 1 mol compound of formula I. The temperature at salt deposition is preferably -10 to 15 deg.C. The compound of formula I is obtained by reacting an optically active (S)-4-[(4-chlorophenyl) (2-pyridyl)methoxy]piperidin with a compound of formula II (W is an eleiminable group; R is a lower alkyl) (e.g. ethyl 4- bromobutanoate) in an inert solvent in the presence of a base and then subjecting the resultant compound of formula III to hydrolysis reaction.
In accordance with the present invention, it has been discovered that compounds which modulate the γ-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone Aβ peptides (such as Aβ37 and Aβ38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the γ-secretase enzyme. Thus, such compounds do not impede other critical functions of the γ-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators. Such screening assays can be performed in a variety of ways, e.g., by assessing whether test compounds: lower the level of Aβ42 peptide, increase the level of Aβ37 and/or Aβ38 peptides, have substantially no effect on the processing of other γ-secretase substrates, and/or interact with at least one component of the γ-secretase complex. Also provided in accordance with the present invention are compounds having gamma-secretase modulatory activity as identified by any of the methods described herein; methods for producing formulations useful for modulating gamma-secretase activity, as well as the resulting formulations; methods for modulating gamma-secretase activity employing compounds identified according to invention methods and/or invention formulations, and the like.
PURPOSE:To provide the title improved stabilizer free from such problems as discomfort, offensive taste, oral stickiness and adhesive force, comprising a dimethylpolysiloxane of a specified viscosity and a water-soluble polymer. CONSTITUTION:The objective artificial tooth stabilizer comprising (A) 40-99wt.% of a compound of the formula (R1 and R2 are each CH3 or OH; (n) is >=40) with 50-15000000 (pref. 100-10000000) cps in the viscosity at 25 deg.C and (B) 1-60wt.% of a water-soluble polymer (e.g. karaya gum, carboxymethylcellulose sodium salt, polyethylene oxide). The present stabilizer gives no offensive taste when used, being excellent in adhesiveness for a long period of time, and also excellent in releaseability from artificial teeth after use. If desired, this stabilizer may further be incorporated with other organopolysiloxane(s).
Microplastics (MPs) are recognized as a major environmental problem due to their ubiquitous presence in ecosystems and bioaccumulation in food chains. Not only humans are continuously exposed to these pollutants through ingestion and inhalation, but recent findings suggest they may trigger vascular inflammation and potentially worsen the clinical conditions of cardiovascular patients. Here we combine headspace analysis by needle trap microextraction-gas chromatography-mass spectrometry (HS-NTME-GC-MS) and biological assays to evaluate the effects of polystyrene, high- and low-density polyethylene MPs on phenotype, metabolic activity, and pro-inflammatory status of Vascular Smooth Muscle Cells (VSMCs) the most prominent cells in vascular walls. Virgin and artificially aged MPs (4 weeks at 40 °C and 750 W/m2 simulated solar irradiation) were comparatively tested at 1 mg/mL to simulate a realistic exposure scenario. Our results clearly show the activation of oxidative stress and inflammatory processes when VSMCs were cultured with aged polymers, with significant overexpression of IL-6 and TNF-α. In addition, volatile organic compounds (VOCs), including pentane, acrolein, propanal, and hexanal as the main components, were released by VSMCs into the headspace. Type-specific VOC response profiles were induced on vascular cells from different MPs.
The study will take place in a quarantine facility. Some volunteers (Donors) will be infected with the influenza virus via droplets into the nose. Other volunteers (Recipients) will then be exposed to them by occupying the same room (in the day time) and taking part in certain activities e.g. playing card games. Some of the Recipients will wear face shields and clean their hands regularly during the times they are with the Donors. The wearing of face shields together with good hand hygiene should reduce the spread of infection through large respiratory droplets and contact with contaminated surfaces but will not prevent infection that occurs through aerosols in the air. Use of symptom diaries and diagnostic tests for influenza will allow the presence of subsequent illness to be identified. Volunteers will be required to participate in the quarantine facility for up to approximately 13 days (typically 9 for Donors and 13 days for Recipients), plus study screening clinics and followup.

Additionally, during the study, environmental sampling will be performed looking for the presence of influenza virus. Air sampling and swabbing of surfaces and objects may provide information enabling us to better understand the routes of transmission.
Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na + ) and calcium (Ca 2+ ) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.
FIELD: medicine, endocrinology, sexual pathology. SUBSTANCE: method involves the use of mixture of biocompatible hydrogel with insulin as medicinal preparation that is administrated by intra-cavernous route. Insulin dose does not exceed 1/2 of daily dose for patient. Preparation is administrated for two stages: firstly, 1/3 of required volume and the remaining dose in 2-3 weeks. Method is the most effective as compared with the known ones, it is simple in fulfillment, reduces by-side effect to minimum and ensures to obtain positive results in 97.5% of patients. Invention can be used for correction of erection in males with diabetes mellitus. EFFECT: improved and enhanced method of correction. 3 cl, 2 ex